A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer

D. T. Ransom, D. Neuberg, Charles Lawrence Loprinzi, D. C. Tormey, R. H. Blum, J. E. Harris, R. F. Asbury, G. Falkson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aim of this pilot study was to estimate the toxicity and response rate of an alternating chemotherapeutic program in chemotherapy-naive metastatic breast cancer patients. Treatment consisted of regimen A (given days 1-28): cyclophosphamide 100 mg/m2 PO days 1-14, doxorubicin 30 mg/m2 i.v. days 1 and 8, and 5-fluorouracil 500 mg/m2 i.v. days 1 and 8 (CAF regimen); regimen B (given days 29-56); dibromodulcitol 135 mg/m2 p.o. days 30-39, mitoxantrone 9 mg/m2 i.v. day 29, and vincristine 1.2 mg/m2 i.v. (maximum 2.0 mg) day 29 (DMV regimen); and regimen C (given days 57-84): thiotepa 12 mg/m2, doxorubicin 45 mg/m2 and vinblastine 4.5 mg/m2 all i.v. on day 57. There were 27 eligible patients with a median age of 51 years (range 34-78). On 14 episodes the leukocyte count fell to <1 X 109/L during the first six cycles of treatment (14% of 99 cycles). There were no treatment-related deaths. Common non-life-threatening toxicities included thrombocytopenia, anemia, vomiting, and alopecia. Despite having no drugs in common, the leukocyte and platelet nadirs after CAF correlated with the nadir counts after DMV (r values of 0.6829 and 0.5892, respectively; p = 0.01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22%) and nine partial responses (39%), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number1
StatePublished - 1991

Fingerprint

Breast Neoplasms
Doxorubicin
Mitolactol
Thiotepa
Mitoxantrone
Vinblastine
Alopecia
Vincristine
Treatment Failure
Leukocyte Count
Fluorouracil
Thrombocytopenia
Cyclophosphamide
Vomiting
Anemia
Leukocytes
Therapeutics
Blood Platelets
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ransom, D. T., Neuberg, D., Loprinzi, C. L., Tormey, D. C., Blum, R. H., Harris, J. E., ... Falkson, G. (1991). A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 14(1), 45-48.

A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. / Ransom, D. T.; Neuberg, D.; Loprinzi, Charles Lawrence; Tormey, D. C.; Blum, R. H.; Harris, J. E.; Asbury, R. F.; Falkson, G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 1, 1991, p. 45-48.

Research output: Contribution to journalArticle

Ransom, DT, Neuberg, D, Loprinzi, CL, Tormey, DC, Blum, RH, Harris, JE, Asbury, RF & Falkson, G 1991, 'A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 14, no. 1, pp. 45-48.
Ransom, D. T. ; Neuberg, D. ; Loprinzi, Charles Lawrence ; Tormey, D. C. ; Blum, R. H. ; Harris, J. E. ; Asbury, R. F. ; Falkson, G. / A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1991 ; Vol. 14, No. 1. pp. 45-48.
@article{dfb2fcb04d1b4eb3a1f0cd53e05f1832,
title = "A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer",
abstract = "The aim of this pilot study was to estimate the toxicity and response rate of an alternating chemotherapeutic program in chemotherapy-naive metastatic breast cancer patients. Treatment consisted of regimen A (given days 1-28): cyclophosphamide 100 mg/m2 PO days 1-14, doxorubicin 30 mg/m2 i.v. days 1 and 8, and 5-fluorouracil 500 mg/m2 i.v. days 1 and 8 (CAF regimen); regimen B (given days 29-56); dibromodulcitol 135 mg/m2 p.o. days 30-39, mitoxantrone 9 mg/m2 i.v. day 29, and vincristine 1.2 mg/m2 i.v. (maximum 2.0 mg) day 29 (DMV regimen); and regimen C (given days 57-84): thiotepa 12 mg/m2, doxorubicin 45 mg/m2 and vinblastine 4.5 mg/m2 all i.v. on day 57. There were 27 eligible patients with a median age of 51 years (range 34-78). On 14 episodes the leukocyte count fell to <1 X 109/L during the first six cycles of treatment (14{\%} of 99 cycles). There were no treatment-related deaths. Common non-life-threatening toxicities included thrombocytopenia, anemia, vomiting, and alopecia. Despite having no drugs in common, the leukocyte and platelet nadirs after CAF correlated with the nadir counts after DMV (r values of 0.6829 and 0.5892, respectively; p = 0.01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22{\%}) and nine partial responses (39{\%}), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months.",
author = "Ransom, {D. T.} and D. Neuberg and Loprinzi, {Charles Lawrence} and Tormey, {D. C.} and Blum, {R. H.} and Harris, {J. E.} and Asbury, {R. F.} and G. Falkson",
year = "1991",
language = "English (US)",
volume = "14",
pages = "45--48",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer

AU - Ransom, D. T.

AU - Neuberg, D.

AU - Loprinzi, Charles Lawrence

AU - Tormey, D. C.

AU - Blum, R. H.

AU - Harris, J. E.

AU - Asbury, R. F.

AU - Falkson, G.

PY - 1991

Y1 - 1991

N2 - The aim of this pilot study was to estimate the toxicity and response rate of an alternating chemotherapeutic program in chemotherapy-naive metastatic breast cancer patients. Treatment consisted of regimen A (given days 1-28): cyclophosphamide 100 mg/m2 PO days 1-14, doxorubicin 30 mg/m2 i.v. days 1 and 8, and 5-fluorouracil 500 mg/m2 i.v. days 1 and 8 (CAF regimen); regimen B (given days 29-56); dibromodulcitol 135 mg/m2 p.o. days 30-39, mitoxantrone 9 mg/m2 i.v. day 29, and vincristine 1.2 mg/m2 i.v. (maximum 2.0 mg) day 29 (DMV regimen); and regimen C (given days 57-84): thiotepa 12 mg/m2, doxorubicin 45 mg/m2 and vinblastine 4.5 mg/m2 all i.v. on day 57. There were 27 eligible patients with a median age of 51 years (range 34-78). On 14 episodes the leukocyte count fell to <1 X 109/L during the first six cycles of treatment (14% of 99 cycles). There were no treatment-related deaths. Common non-life-threatening toxicities included thrombocytopenia, anemia, vomiting, and alopecia. Despite having no drugs in common, the leukocyte and platelet nadirs after CAF correlated with the nadir counts after DMV (r values of 0.6829 and 0.5892, respectively; p = 0.01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22%) and nine partial responses (39%), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months.

AB - The aim of this pilot study was to estimate the toxicity and response rate of an alternating chemotherapeutic program in chemotherapy-naive metastatic breast cancer patients. Treatment consisted of regimen A (given days 1-28): cyclophosphamide 100 mg/m2 PO days 1-14, doxorubicin 30 mg/m2 i.v. days 1 and 8, and 5-fluorouracil 500 mg/m2 i.v. days 1 and 8 (CAF regimen); regimen B (given days 29-56); dibromodulcitol 135 mg/m2 p.o. days 30-39, mitoxantrone 9 mg/m2 i.v. day 29, and vincristine 1.2 mg/m2 i.v. (maximum 2.0 mg) day 29 (DMV regimen); and regimen C (given days 57-84): thiotepa 12 mg/m2, doxorubicin 45 mg/m2 and vinblastine 4.5 mg/m2 all i.v. on day 57. There were 27 eligible patients with a median age of 51 years (range 34-78). On 14 episodes the leukocyte count fell to <1 X 109/L during the first six cycles of treatment (14% of 99 cycles). There were no treatment-related deaths. Common non-life-threatening toxicities included thrombocytopenia, anemia, vomiting, and alopecia. Despite having no drugs in common, the leukocyte and platelet nadirs after CAF correlated with the nadir counts after DMV (r values of 0.6829 and 0.5892, respectively; p = 0.01). Among the 23 patients with measurable and/or evaluable disease there were five complete responses (22%) and nine partial responses (39%), with a median time to treatment failure of 29 weeks. The overall median survival was 19 months.

UR - http://www.scopus.com/inward/record.url?scp=0026080869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026080869&partnerID=8YFLogxK

M3 - Article

C2 - 1898999

AN - SCOPUS:0026080869

VL - 14

SP - 45

EP - 48

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 1

ER -